Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Shares, par value (euro)0.12 per share
-
Shares outstanding
-
22,421,536
-
Total 13F shares
-
7,249,042
-
Share change
-
-379,372
-
Total reported value
-
$588,213,325
-
Put/Call ratio
-
163%
-
Price per share
-
$81.07
-
Number of holders
-
57
-
Value change
-
-$18,568,618
-
Number of buys
-
35
-
Number of sells
-
25
Institutional Holders of CureVac N.V. - Common Shares, par value (euro)0.12 per share (CVAC) as of Q4 2020
As of 31 Dec 2020,
CureVac N.V. - Common Shares, par value (euro)0.12 per share (CVAC) was held by
57 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,249,042 shares.
The largest 10 holders included
BAILLIE GIFFORD & CO, PRICE T ROWE ASSOCIATES INC /MD/, GEODE CAPITAL MANAGEMENT, LLC, DEUTSCHE BANK AG\, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Samsara BioCapital, LLC, D. E. Shaw & Co., Inc., JANE STREET GROUP, LLC, DekaBank Deutsche Girozentrale, and HILLHOUSE CAPITAL ADVISORS, LTD..
This page lists
58
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.